SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001516551-22-000037
Filing Date
2022-10-19
Accepted
2022-10-18 17:44:24
Documents
14
Period of Report
2022-10-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20221014.htm   iXBRL 8-K 49297
2 EX-10.1 exhibit101_221011xskyexpro.htm EX-10.1 27779
3 EX-10.2 exhibit102_221014agmtloana.htm EX-10.2 75713
  Complete submission text file 0001516551-22-000037.txt   303477

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20221014.xsd EX-101.SCH 1921
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20221014_lab.xml EX-101.LAB 22080
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20221014_pre.xml EX-101.PRE 11526
8 EXTRACTED XBRL INSTANCE DOCUMENT skye-20221014_htm.xml XML 10700
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55136 | Film No.: 221316789
SIC: 2834 Pharmaceutical Preparations